FDA Approves Drugs for Cervical, Breast Cancer - Cancer Currents Blog

National Cancer Institute sent this bulletin at 11/01/2021 11:00 AM EDT
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

 

 

FDA Approves Drugs for Advanced Cervical Cancer, Most Common Type of Breast Cancer
10/27/2021

Two previously published NCI Cancer Currents blog posts have been updated with new information about recent drug approvals by the Food and Drug Administration (FDA).
New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma, originally published August 2, 2018, now includes an update about FDA’s approval of pembrolizumab as part of a combination therapy and as a single agent for people with advanced cervical cancer.
 
An update has also been added to Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer with information about FDA’s approval of abemaciclib for some people with HR-positive, HER2-negative breast cancer following surgery. The original post was published January 26, 2021.